Art. -Nr.: HY-15453

Devimistat

(Synonyms: CPI-613)

26 Cited Publications

Kundenbewertung

Based on 26 publication(s) in Google Scholar

Devimistat is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.57%
CAS. Nr.: 95809-78-2
Formel: C₂₂H₂₈O₂S₂
Molecular Weight:388.59

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Devimistat Chemical Structure

CAS. Nr.: 95809-78-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- Clinical Trial
Chemical Information
Publications (26)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Devimistat is a mitochondrial metabolism inhibitor. Devimistat is a lipoic acid antagonist that abrogates mitochondrial energy metabolism to induce apoptosis in various cancer cells^[1].

IC₅₀ & Target

mitochondrial metabolism^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>50 μM Compound: 2	Antiproliferative activity against human A549 cells by CCK8 assay Antiproliferative activity against human A549 cells by CCK8 assay	[PMID: 37939862]
HepG2	IC₅₀	>50 μM Compound: 2	Antiproliferative activity against human HepG2 cells by CCK8 assay Antiproliferative activity against human HepG2 cells by CCK8 assay	[PMID: 37939862]
K562	IC₅₀	>50 μM Compound: 2	Antiproliferative activity against human K562 cells by CCK8 assay Antiproliferative activity against human K562 cells by CCK8 assay	[PMID: 37939862]
MCF7	IC₅₀	>50 μM Compound: 2	Antiproliferative activity against human MCF7 cells by CCK8 assay Antiproliferative activity against human MCF7 cells by CCK8 assay	[PMID: 37939862]
MDA-MB-231	IC₅₀	>50 μM Compound: 2	Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay	[PMID: 37939862]
PANC-1	IC₅₀	>50 μM Compound: 2	Antiproliferative activity against human PANC-1 cells by CCK8 assay Antiproliferative activity against human PANC-1 cells by CCK8 assay	[PMID: 37939862]

In Vitro

Devimistat induces apoptosis of GPM-2 gastric cancer cells. Devimistat targets the altered form of mitochondrial energy metabolism utilized by tumor cells. The change in mitochondrial enzyme activities and cellular redox status induced by devimistat leads to cell death, including apoptosis^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 95809-78-2
Appearance Solid
Molecular Weight 388.59
Formel C₂₂H₂₈O₂S₂
Color White to off-white
SMILES

O=C(O)CCCCC(SCC1=CC=CC=C1)CCSCC2=CC=CC=C2
Synonyms

CPI-613
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (26)

All In Vivo Efficacy StudyBio/Physico-chemical AssayCell Proliferation/Viability AssayWBRT-PCR

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

A two-strata energy flux system driven by a stress hormone prioritizes cardiac energetics. [Abstract]

2025 Sep 26;10(1):315. PMID: 40998786

Devimistat purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Sep 26;10(1):315. [Abstract]

Cpi-613 (1 mg/mouse; i.p.). Effects of Cpi-613 in rhFGF21-promoted improvements of Echo parameters EF, FS, CO, LVEDD and LVESD in Fgf21-null mice fasted for 12 hours.
Signal Transduct Target Ther

Suppression of PFKFB3-driven glycolysis restrains endothelial-to-mesenchymal transition and fibrotic response. [Abstract]

2022 Sep 1;7(1):303. PMID: 36045132
Nat Genet

Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. [Abstract]

2025 Mar;57(3):680-693. PMID: 40069506

Devimistat purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693. [Abstract]

CPI-613 (0-100 μM; 24 h). A375 cells treated with OGDH inhibitor (CPI-613), co-cultured with T cells, and stained with crystal violet to measure survival.

Devimistat purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693. [Abstract]

CPI-613 (0-100 μM; 24 h). Western blot analysis of PD-L1 protein levels in A375 and SK-MEL-28 cells treated with OGDH inhibitor (CPI-613).

Devimistat purchased from MedChemExpress. Usage Cited in: Nat Genet. 2025 Mar;57(3):680-693. [Abstract]

CPI-613 (75-150 μM; 24 h). mRNA levels of PD-L1 in A375 cells treated with 3-NPA, DMM, or CPI-613.
Adv Sci (Weinh)

Metabolic Imbalance Triggers Adaptive Remodeling to Accelerate Diploidization in Murine Haploid Embryonic Stem Cells. [Abstract]

2026 Apr 22:e22570. PMID: 42018132
Adv Sci (Weinh)

Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. [Abstract]

2026 Apr;13(21):e13341. PMID: 41684301
Adv Sci (Weinh)

NADH-Reductive Stress Induced by Dihydrolipoamide Dehydrogenase Activation Contributes to Cuproptosis. [Abstract]

2025 Dec 5:e20444. PMID: 41346305

Devimistat purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Dec 5:e20444. [Abstract]

NADH level and NADH/NAD⁺ ratio of SH‐SY5Y cells treated with 250 µM CuSO₄ and 4 nM CPI‐613 (CPI) for 18 h.
Adv Sci (Weinh)

Extracellularly Detectable Electrochemical Signals of Living Cells Originate from Metabolic Reactions. [Abstract]

2023 Mar;10(9):e2207084. PMID: 36737855
Sci Adv

Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors. [Abstract]

2025 Jul 18;11(29):eadw5228. PMID: 40668928
Sci Adv

Acute myeloid leukemia mitochondria hydrolyze ATP to support oxidative metabolism and resist chemotherapy. [Abstract]

2025 Apr 11;11(15):eadu5511. PMID: 40203117
Nano Today

2023 Dec, 53, 102009.
Cell Rep Med

KRASG12D-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. [Abstract]

2025 Feb 18;6(2):101966. PMID: 39970873
J Immunother Cancer

Inhibition of TCA cycle improves the anti-PD-1 immunotherapy efficacy in melanoma cells via ATF3-mediated PD-L1 expression and glycolysis. [Abstract]

2023 Sep;11(9):e007146. PMID: 37678921
Pharmacol Res

YBX1-LDHB axis orchestrates pyruvate production from lactate to promote ICC initiation and development. [Abstract]

2026 Feb:224:108110. PMID: 41577157
Cell Death Dis

Targeting mitochondrial α-ketoglutarate sequestration disables dual oncogenic drivers and metabolic adaptability in pancreatic ductal adenocarcinoma. [Abstract]

2026 Jun 25. PMID: 42350388
Nano Res

2022.
Free Radic Biol Med

Potassium ion efflux induces exaggerated mitochondrial damage and non-pyroptotic necrosis when energy metabolism is blocked. [Abstract]

2024 Feb 20:212:117-132. PMID: 38151213
Br J Pharmacol

Thiamine deficiency aggravates experimental colitis in mice by promoting glycolytic reprogramming in macrophages. [Abstract]

2025 May;182(9):1897-1911. PMID: 39890689
JHEP Rep

PLOD1 promotes the malignancy of hepatocellular carcinoma by facilitating the NF-κB/IL-6/STAT3-dependent TCA cycle. [Abstract]

2025 Jan 20;7(5):101329. PMID: 40290518
Aging Cell

Decreased Glucose Metabolism and Declined Chaperones Are Unique Features Required for the Survival of Senescent Fibroblasts and Pyruvate Dehydrogenase Is a Potent Senolytic Target. [Abstract]

2026 Mar;25(3):e70434. PMID: 41786630
Cell Rep

Blockage of citrate export prevents TCA cycle fragmentation via Irg1 inactivation. [Abstract]

2022 Feb 15;38(7):110391. PMID: 35172156
Elife

MARCH5 mediates NOXA-dependent MCL1 degradation driven by kinase inhibitors and integrated stress response activation. [Abstract]

2020 Jun 2;9:e54954. PMID: 32484436
JCI Insight

OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma. [Abstract]

2024 Mar 14;9(8):e172565. PMID: 38483541
Cell Prolif

Dissection of Mitochondrial Function via Chemical Perturbation and Single-Cell Profiling. [Abstract]

2026 Apr 27:e70216. PMID: 42044679
Commun Biol

DLST-dependence dictates metabolic heterogeneity in TCA-cycle usage among triple-negative breast cancer. [Abstract]

2021 Nov 16;4(1):1289. PMID: 34785772
Cancers (Basel)

Deciphering the Metabolic Basis and Molecular Circuitry of the Warburg Paradox in Lymphoma. [Abstract]

2024 Oct 25;16(21):3606. PMID: 39518046
Cancers (Basel)

α-Ketoglutarate-Mediated DNA Demethylation Sustains T-Acute Lymphoblastic Leukemia upon TCA Cycle Targeting. [Abstract]

2022 Jun 16;14(12):2983. PMID: 35740646

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (257.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.5734 mL

12.8670 mL

25.7341 mL

5 mM

0.5147 mL

2.5734 mL

5.1468 mL

10 mM

0.2573 mL

1.2867 mL

2.5734 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.35 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 2% DMSO 40% PEG300 5% Tween-80 53% Saline

Solubility: 2 mg/mL (5.15 mM); Suspended solution; Need ultrasonic

Protocol 5

Add each solvent one by one: 2% DMSO 98% (20% SBE-β-CD in Saline)

Solubility: ≥ 2 mg/mL (5.15 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
SDS (399 KB)
- English - EN (399 KB)
- Français - FR (399 KB)
- Deutsch - DE (399 KB)
- Norwegian - NO (399 KB)
- Español - ES (399 KB)
- Swedish - SV (399 KB)
- Italian - IT (399 KB)
- Korean - KR (399 KB)
- Portuguese - PT (399 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Sakuratani T, et al. Downregulation of ARID1A in gastric cancer cells: a putative protective molecular mechanism against the Harakiri-mediated apoptosis pathway. Virchows Arch. 2021;478(3):401-411. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.5734 mL	12.8670 mL	25.7341 mL	64.3352 mL
	5 mM	0.5147 mL	2.5734 mL	5.1468 mL	12.8670 mL
	10 mM	0.2573 mL	1.2867 mL	2.5734 mL	6.4335 mL
	15 mM	0.1716 mL	0.8578 mL	1.7156 mL	4.2890 mL
	20 mM	0.1287 mL	0.6434 mL	1.2867 mL	3.2168 mL
	25 mM	0.1029 mL	0.5147 mL	1.0294 mL	2.5734 mL
	30 mM	0.0858 mL	0.4289 mL	0.8578 mL	2.1445 mL
	40 mM	0.0643 mL	0.3217 mL	0.6434 mL	1.6084 mL
	50 mM	0.0515 mL	0.2573 mL	0.5147 mL	1.2867 mL
	60 mM	0.0429 mL	0.2145 mL	0.4289 mL	1.0723 mL
	80 mM	0.0322 mL	0.1608 mL	0.3217 mL	0.8042 mL
	100 mM	0.0257 mL	0.1287 mL	0.2573 mL	0.6434 mL

Keywords

Devimistat

26 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Devimistat

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Glutamine Metabolism Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Rare Diseases Drug Library

Cuproptosis Compound Library

Cancer Stem Cells Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Cell Death Library

Bioactive Compound Library Max

Anti-Aging Compound Library Mini

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Devimistat

Biologische Aktivität

Chemical Information

Publications (26)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Devimistat Related Classifications

HY-15453 Related Classifications